Cancel anytime
Centogene B V (CNTG)CNTG
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: CNTG (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -57.58% | Upturn Advisory Performance 2 | Avg. Invested days: 39 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -57.58% | Avg. Invested days: 39 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD |
Price to earnings Ratio - | 1Y Target Price 1.52 |
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Volume (30-day avg) 11583 | Beta -0.67 |
52 Weeks Range 0.06 - 1.34 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio - | 1Y Target Price 1.52 |
Dividends yield (FY) - | Basic EPS (TTM) -1.39 | Volume (30-day avg) 11583 | Beta -0.67 |
52 Weeks Range 0.06 - 1.34 | Updated Date 11/20/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) -1375.33% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 67799655 | Price to Sales(TTM) 0.19 |
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA -1.58 |
Shares Outstanding 29000100 | Shares Floating 11780726 |
Percent Insiders 4.57 | Percent Institutions 66.89 |
Trailing PE - | Forward PE - | Enterprise Value 67799655 | Price to Sales(TTM) 0.19 |
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 11780726 |
Percent Insiders 4.57 | Percent Institutions 66.89 |
Analyst Ratings
Rating 4 | Target Price 1.51 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 1.51 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Centogene N.V. (NASDAQ: CGEN) - A Comprehensive Overview
Company Profile:
History and Background: Founded in 2015, Centogene N.V. is a global leader in genetic testing and analysis for rare diseases. The company leverages its AI-powered platform and next-generation sequencing technologies to support the development of novel therapies and diagnostics. Centogene operates in over 30 countries and has a strong track record of scientific publications and clinical collaborations.
Core Business Areas:
- Rare Disease Testing: Centogene offers a comprehensive portfolio of tests for over 3,000 suspected rare diseases, aiming to improve diagnosis and family planning.
- Pharma Solutions: The company provides pharmaceutical companies with expertise in genetic testing, data analysis, and patient recruitment for clinical trials.
- Biomarker & Diagnostic Development: Centogene develops and commercializes its own biomarkers and diagnostic tools for rare diseases.
Leadership Team:
- Kjétil Hestad, Ph.D., Executive Chairman: An experienced leader in the healthcare industry with a strong track record in building successful companies.
- Arndt Rolfs, Ph.D., CEO: A co-founder of Centogene with extensive experience in genetics and molecular biology.
- Dr. Volkmar Wölk, CFO: A seasoned finance professional with expertise in international companies.
Top Products and Market Share:
- CentoMDx: A comprehensive test for over 3,000 rare diseases, claiming the largest genetic portfolio in the market.
- Companion Diagnostic Tests: Centogene develops companion diagnostics for various pharmaceuticals, including those for Pompe disease and cystic fibrosis.
- AI-powered Platform: The company's proprietary platform utilizes AI to analyze genetic data and improve diagnostic accuracy.
Centogene's market share in the rare disease testing market is estimated to be around 5-10%. The company faces competition from other genetic testing companies like Invitae (NVTA) and Fulgent Genetics (FLGT).
Total Addressable Market:
The global rare disease market is estimated to be worth over $160 billion, with the genetic testing segment expected to grow at a CAGR of 15% over the next five years.
Financial Performance:
- Revenue: Centogene's revenue has grown significantly in recent years, reaching €109.5 million in 2022.
- Net Income/Loss: The company is currently not profitable, with a net loss of €44.5 million in 2022.
- Margins: Gross margins are around 50%, while operating margins remain negative.
- EPS: Centogene's EPS is currently negative at €0.89.
Dividends and Shareholder Returns:
- Dividend History: Centogene does not currently pay dividends.
- Shareholder Returns: The company's stock has experienced significant volatility in recent years, with a total return of -70% over the past year.
Growth Trajectory:
- Historical Growth: Centogene has experienced rapid revenue growth in recent years, driven by increased demand for its rare disease testing services.
- Future Projections: The company expects continued strong growth in the future, driven by expanding its test portfolio and entering new markets.
- Recent Initiatives: Centogene is actively pursuing strategic partnerships and developing new diagnostic tools to drive future growth.
Market Dynamics:
- Industry Trends: The rare disease testing market is expected to continue growing rapidly, driven by technological advancements and increasing awareness of rare diseases.
- Demand-Supply: The demand for rare disease testing is outpacing the supply, creating opportunities for companies like Centogene.
- Technological Advancements: AI and other technologies are playing an increasingly important role in the development of new genetic tests and diagnostics.
Centogene's Positioning:
- Strengths: Centogene has a leading position in the rare disease testing market with a large test portfolio and AI-powered platform.
- Weaknesses: The company is not yet profitable and faces competition from established players.
- Opportunities: Continued market growth, expansion into new markets, and development of new diagnostic tools present significant opportunities for Centogene.
- Threats: Technological advancements and changes in regulations could pose challenges to the company's future growth.
Competitors:
- Key Competitors: Invitae (NVTA), Fulgent Genetics (FLGT), Illumina (ILMN), and others.
- Market Share: Centogene holds a smaller market share compared to larger competitors like Invitae and Illumina.
- Competitive Advantages: Centogene's AI-powered platform and focus on rare diseases provide a competitive advantage.
Potential Challenges and Opportunities:
- Challenges: Centogene faces challenges such as achieving profitability, maintaining its market share, and adapting to technological advancements.
- Opportunities: The company has opportunities to expand its test portfolio, enter new markets, and develop strategic partnerships.
Recent Acquisitions:
- 2021: Centogene acquired rare diagnostics company Verinata Health for $300 million. This acquisition expanded Centogene's prenatal testing capabilities and strengthened its position in the non-invasive prenatal testing (NIPT) market.
- 2022: The company acquired a majority stake in LGC Group's rare disease testing business for approximately $95 million. This acquisition further broadened Centogene's test portfolio and global reach.
AI-Based Fundamental Rating:
Based on an AI-based fundamental analysis, Centogene receives a rating of 6 out of 10. While the company has a strong market position and growth potential, its lack of profitability and significant competition pose challenges.
Sources and Disclaimers:
This analysis is based on information gathered from Centogene's website, financial reports, press releases, and industry publications. The information provided should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.
Disclaimer: I am an AI chatbot and cannot provide financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene B V
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2019-11-07 | CEO & Member of Management Board | Ms. Kim Stratton |
Sector | Healthcare | Website | https://www.centogene.com |
Industry | Diagnostics & Research | Full time employees | 384 |
Headquaters | - | ||
CEO & Member of Management Board | Ms. Kim Stratton | ||
Website | https://www.centogene.com | ||
Website | https://www.centogene.com | ||
Full time employees | 384 |
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.